Market Cap | 321.66M | P/E | - | EPS this Y | 14.30% | Ern Qtrly Grth | - |
Income | -40.44M | Forward P/E | -10.81 | EPS next Y | -8.30% | 50D Avg Chg | 45.00% |
Sales | 174.5M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 127.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -6.00% |
Recommedations | 1.70 | Quick Ratio | 0.65 | Shares Outstanding | 210.29M | 52W Low Chg | 618.00% |
Insider Own | 2.17% | ROA | -8.84% | Shares Float | 190.32M | Beta | 0.77 |
Inst Own | 27.01% | ROE | - | Shares Shorted/Prior | 19.06M/18.95M | Price | 1.73 |
Gross Margin | 82.29% | Profit Margin | -23.18% | Avg. Volume | 2,142,154 | Target Price | 5.50 |
Oper. Margin | -19.99% | Earnings Date | Nov 6 | Volume | 2,121,982 | Change | -5.98% |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
HC Wainwright & Co. | Buy | Sep 6, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
HC Wainwright & Co. | Buy | Mar 28, 24 |
HC Wainwright & Co. | Buy | Mar 15, 24 |
HC Wainwright & Co. | Buy | Nov 17, 23 |
HC Wainwright & Co. | Buy | Sep 27, 23 |
HC Wainwright & Co. | Buy | Aug 28, 23 |
HC Wainwright & Co. | Neutral | Aug 11, 23 |
HC Wainwright & Co. | Neutral | Jun 21, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Hadas Nicole R. | SVP, Chief Legal Off.. SVP, Chief Legal Officer | May 24 | Sell | 1.22 | 63,186 | 77,087 | 524,344 | 05/25/23 |
Dahan Michel | SVP, Chief Operating.. SVP, Chief Operating Officer | May 24 | Sell | 1.22 | 95,478 | 116,483 | 574,037 | 05/25/23 |
Butler John P. | CEO and President CEO and President | Feb 28 | Sell | 2.17 | 79,026 | 171,486 | 1,403,247 | 03/02/22 |
Burke Steven Keith | SVP, Chief Medical O.. SVP, Chief Medical Officer | Feb 28 | Sell | 2.17 | 15,056 | 32,672 | 217,663 | 03/02/22 |
Cotreau Violetta | SVP, Chief Accountin.. SVP, Chief Accounting Officer | Feb 28 | Sell | 2.15 | 3,946 | 8,484 | 29,121 | 03/02/22 |
Dahan Michel | SVP, Chief Operating.. SVP, Chief Operating Officer | Feb 28 | Sell | 2.17 | 21,533 | 46,727 | 297,017 | 03/02/22 |
Faulkingham Dell | SVP, CCO SVP, CCO | Feb 28 | Sell | 2.17 | 13,184 | 28,609 | 173,841 | 03/02/22 |
Hadas Nicole R. | SVP, Chief Legal Off.. SVP, Chief Legal Officer | Feb 28 | Sell | 2.17 | 21,062 | 45,705 | 304,241 | 03/02/22 |
Spellman David A | SVP, CFO and Treasur.. SVP, CFO and Treasurer | Feb 28 | Sell | 2.16 | 8,203 | 17,718 | 128,599 | 03/02/22 |
Faulkingham Dell | CCO CCO | Mar 02 | Sell | 3.4 | 6,749 | 22,947 | 128,825 | 03/02/21 |
Hadas Nicole R. | SVP, Chief Legal Off.. SVP, Chief Legal Officer | Mar 02 | Sell | 3.4 | 14,285 | 48,569 | 263,171 | 03/02/21 |